Teladoc Health, Inc. (TDOC) PE Ratio: N/A
The P/E ratio for Teladoc Health, Inc. (TDOC) is N/A as of Tuesday, June 23, 2026.
TDOC PE Ratio Metrics
PE RATIO
N/A
TDOC Competitors' PE Ratio
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Teladoc Health, Inc. (TDOC) | $1.37B | N/A | N/A | N/A | N/A |
| DENTSPLY SIRONA Inc. (XRAY)vs › | $2.03B | N/A | 23.81 | 50.79 | 57.43 |
| Shoulder Innovations, Inc. (SI)vs › | $366.44M | N/A | N/A | N/A | N/A |
| TransMedics Group, Inc. (TMDX)vs › | $2.61B | 17.28 | 48.22 | 543.27 | 543.27 |
| 23andMe Holding Co. (ME)vs › | $15.31M | N/A | N/A | N/A | N/A |
| Hims & Hers Health, Inc. (HIMS)vs › | $7.48B | N/A | 61.96 | 88.48 | 88.48 |
| Oscar Health, Inc. (OSCR)vs › | $7.50B | N/A | 60.92 | 60.92 | 60.92 |
| Bio-Rad Laboratories, Inc. (BIO)vs › | $7.60B | 46.31 | 24.74 | 24.74 | 12.79 |
| Tempus AI, Inc. (TEM)vs › | $8.35B | N/A | N/A | N/A | N/A |
| Charles River Laboratories International, Inc. (CRL)vs › | $8.75B | N/A | 225.66 | 91.39 | 72.20 |
P/E Comparison
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E Calculation
View All Analyst EstimatesForward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$7.58
Forward EPS (Est.)
$-0.64
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
Teladoc Health, Inc. PE Ratio Formula & Definition
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
About Teladoc Health, Inc.
Teladoc Health, Inc. offers remote medical services to individuals both domestically in the United States and internationally. Their extensive range of solutions covers a wide array of health needs, from routine and acute conditions to complex and long-term illnesses such as diabetes, hypertension, chronic kidney disease, cancer, congestive heart failure, and various mental health issues. The company delivers numerous programs, including virtual primary and specialized medical care, management for chronic diseases, expert second opinion services, mental wellness support, and core platform and service offerings. They serve a diverse client base, including corporations, health insurance providers, hospitals and healthcare systems, financial service companies, and individual patients. The Teladoc, Livongo, and BetterHelp brands fall under their purview. Founded in 2002, the company, which operated as Teladoc, Inc. until its renaming in August 2018, is based in Purchase, New York.
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- CEO
- Charles Divita